Pollack A - Search Results

1

Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.

Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A. Cowen D, et al. Among authors: pollack a. Clin Cancer Res. 2002 May;8(5):1148-54. Clin Cancer Res. 2002. PMID: 12006531

2

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Pollack A, et al. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105. doi: 10.1016/s0360-3016(02)02829-8. Int J Radiat Oncol Biol Phys. 2002. PMID: 12128107 Clinical Trial.

3

Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer.

Pollack A, Kuban DA, Zagars GK. Pollack A, et al. Urology. 2002 Sep;60(3 Suppl 1):22-30; discussion 30-1. doi: 10.1016/s0090-4295(02)01564-9. Urology. 2002. PMID: 12231041 Review.

4

Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.

Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Pollack A, et al. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):677-85. doi: 10.1016/s0360-3016(02)02977-2. Int J Radiat Oncol Biol Phys. 2002. PMID: 12377318 Clinical Trial.

5

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.

Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T. Pollack A, et al. Cancer. 2003 Apr 1;97(7):1630-8. doi: 10.1002/cncr.11230. Cancer. 2003. PMID: 12655519 Free article.

6

Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.

Zagars GK, Pollack A, von Eschenbach AC. Zagars GK, et al. Among authors: pollack a. Cancer. 1997 Apr 1;79(7):1370-80. Cancer. 1997. PMID: 9083160

7

The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation.

Pollack A, Troncoso P, Zagars GK, von Eschenbach AC, Mak AC, Wu CS, Terry NH. Pollack A, et al. Prostate. 1997 Apr 1;31(1):21-8. doi: 10.1002/(sici)1097-0045(19970401)31:1<21::aid-pros4>3.0.co;2-l. Prostate. 1997. PMID: 9108882

8

Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.

Zagars GK, Pollack A, von Eschenbach AC. Zagars GK, et al. Among authors: pollack a. Urology. 1997 Mar;49(3):327-34. doi: 10.1016/S0090-4295(96)00619-X. Urology. 1997. PMID: 9123693

9

Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.

Lankford SP, Pollack A, Zagars GK. Lankford SP, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):327-33. doi: 10.1016/s0360-3016(96)00627-x. Int J Radiat Oncol Biol Phys. 1997. PMID: 9226319

10

Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation.

Zagars GK, Pollack A, von Eschenbach AC. Zagars GK, et al. Among authors: pollack a. Cancer. 1997 Aug 15;80(4):764-75. Cancer. 1997. PMID: 9264361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

969 results

Search Page

Filters